Stocktoria

LianBio LIANY

OTC · stock · Pharmaceutical Preparations · website · IPO 2021-10-28

LianBio statistics & valuation

Market cap$12.5M
P / B0.0×
Return on equity-37.6%
Return on capital-42.3%

Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022
Operating margin (%)
202020212022
Return on equity (%)
-50.70% -37.60% 202020212022
Shares outstanding
20.5M 107.3M 107.9M 202020212022
Net debt ($)
202020212022
Share buybacks ($)
202020212022
Return on assets (%)
-50.00% -46.00% -34.50% 202020212022
Free cash flow margin (%)
202020212022
Debt / equity (×)
202020212022
EPS ($)
-$11.58 -$5.71 -$1.02 202020212022

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2022FY2021FY2020
Return on assets-34.5%-46.0%-50.0%
Return on equity-37.6%-50.7%105.1%
Current ratio13.2426.4844.45

Computed from company filings · US · as of 2022-12-31. Facts plus Stocktoria's own computed scores — not investment advice.